Validation of biomarkers of aging.
Mahdi MoqriChiara M S HerzogJesse R PoganikAlbert K YingJamie N JusticeDaniel W BelskyAlbert T Higgins-ChenBrian H ChenAlan A CohenGeorg FuellenSara HäggRiccardo E MarioniMartin WidschwendterKristen FortneyPeter O FedichevAlex ZhavoronkovNir BarzilaiJessica A Lasky-SuDouglas P KielBrian Keith KennedySteven R CummingsPieternella Eline SlagboomEric VerdinAndrea B MaierVittorio SebastianoMichael Paul SnyderVadim N GladyshevSteve HorvathLuigi FerruciPublished in: Nature medicine (2024)
The search for biomarkers that quantify biological aging (particularly 'omic'-based biomarkers) has intensified in recent years. Such biomarkers could predict aging-related outcomes and could serve as surrogate endpoints for the evaluation of interventions promoting healthy aging and longevity. However, no consensus exists on how biomarkers of aging should be validated before their translation to the clinic. Here, we review current efforts to evaluate the predictive validity of omic biomarkers of aging in population studies, discuss challenges in comparability and generalizability and provide recommendations to facilitate future validation of biomarkers of aging. Finally, we discuss how systematic validation can accelerate clinical translation of biomarkers of aging and their use in gerotherapeutic clinical trials.